IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 290, Issue 4, 2006, Pages

  Brand, Stephan ^a   Beigel, Florian ^a   Olszak, Torsten ^a   Zitzmann, Kathrin ^a   Eichhorst, Sören T ^a   Otte, Jan Michel ^b   Diepolder, Helmut ^a   Marquardt, Andreas ^c   Jagla, Wolfgang ^c   Popp, Andreas ^c   Leclair, Stéphane ^c   Herrmann, Karin ^a   Seiderer, Julia ^a   Ochsenkühn, Thomas ^a   Göke, Burkhard ^a   Auernhammer, Christoph J ^a   Dambacher, Julia ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c Ingenium Pharmaceuticals AG   (Germany)

Author keywords

Defensin; Interleukin 10 like cytokines; Interleukin 22

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; BETA DEFENSIN 2; DEFENSIN; DEXTRAN SULFATE; FAS ANTIGEN; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN RECEPTOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT1 PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TETRAZOLIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; COLITIS; CROHN DISEASE; ENTERITIS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WOUND; WOUND HEALING;

CELL MOVEMENT; CELLS, CULTURED; CROHN DISEASE; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKINS; INTESTINAL MUCOSA;

EID: 33645829078     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00513.2005     Document Type: Article

References (57)

1. Abreu MT, Palladino AA, Arnold ET, Kwon RS, and McRoberts JA. Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells. Gastroenterology 119: 1524-1536, 2000.
2. Aggarwal S, Xie MH, Maruoka M, Foster J, and Gurney AL. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 21: 1047-1053, 2001.
3. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, and Fujiyama Y. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984, 2005.
4. Auernhammer CJ, Bousquet C, and Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci USA 96: 6964-6969, 1999.
5. Bonacchi A, Romagnani P, Romanelli RG, Efsen E, Annunziato F, Lasagni L, Francalanci M, Serio M, Laffi G, Pinzani M, Gentilini P, and Marra F. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 276: 9945-9954, 2001.
6. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, and Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174: 3695-3702, 2005.
7. Bouma G and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533, 2003.
8. Brand S, Beigel F, Dambacher J, Olszak T, Eichhorst ST, Zitzmann K, Auernhammer C, and Diepolder H. The novel cytokines IL-28A and IL-29 exhibit antiproliferative and antiviral properties in liver cells (Abstract). Gastroenterology 128: A751, 2005.
9. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Goke B, and Dambacher J. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289: G960-G968, 2005.
10. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Goeke B, Diepolder H, Adler B, Auernhammer C, and Dambacher J. The novel lambda-interferons IL-28A and IL-29 mediate proinflammatory, antiproliferative, and antiviral signals in intestinal epithelial cells. Gastroenterology 129: 371, 2005.
11. Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, Göke B, and Eichhorst ST. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 310: 117-130, 2005.
12. Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, Seiderer J, Tillack C, Konrad A, Göke B, Ochsenkühn T, and Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am J Gastroenterol 101: 99-106, 2006.
13. Brand S, Sakaguchi T, Gu X, Colgan SP, and Reinecker HC. Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. Gastroenterology 122: 166-177, 2002.
14. Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Goke B, Lohse P, and Ochsenkuhn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 11: 645-652, 2005.
15. Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Goke B, Diepolder H, and Auernhammer CJ. SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 331: 543-548, 2005.
16. Buhner S, Buning C, Genschel J, Kling K, Hermann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, and Lochs H. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. In press.
17. Conti P, Kempuraj D, Frydas S, Kandere K, Boucher W, Letourneau R, Madhappan B, Sagimoto K, Christodoulou S, and Theoharides TC. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol Lett 88: 171-174, 2003.
18. Dignass AU and Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 105: 1323-1332, 1993.
19. Donnelly RP, Sheikh F, Kotenko SV, and Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 76: 314-321, 2004.
20. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, and Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665, 1997.
21. Dumoutier L, Lejeune D, Colau D, and Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 166: 7090-7095, 2001.
22. Dumoutier L, Louahed J, and Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 164: 1814-1819, 2000.
23. Dumoutier L, Van Roost E, Colau D, and Renauld JC. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 97: 10144-10149, 2000.
24. Eichhorst ST, Krueger A, Muerkoster S, Fas SC, Golks A, Gruetzner U, Schubert L, Opelz C, Bilzer M, Gerbes AL, and Krammer PH. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 10: 602-609, 2004.
25. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, and Liu ET. Differential activation of the Ras/ extracellular-signal- regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 16: 135-145, 1996.
26. Galibert L, Diemer GS, Liu Z, Johnson RS, Smith JL, Walzer T, Comeau MR, Rauch CT, Wolfson MF, Sorensen RA, Van der Vuurst de Vries AR, Branstetter DG, Koelling RM, Scholler J, Fanslow WC, Baum PR, Derry JM, and Yan W. Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule. J Biol Chem 280: 21955-21964, 2005.
27. Graness A, Chwieralski CE, Reinhold D, Thim L, and Hoffmann W. Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion. J Biol Chem 277: 18440-18446, 2002.
28. Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 4: 669-677, 2004.
29. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, and Mathew CG. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357: 1925-1928, 2001.
30. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, and Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14, 2002.
31. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, and Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603, 2001.
32. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, and Pestka S. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rβ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 276: 2725-2732, 2001.
33. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, and Pestka S. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 166: 7096-7103, 2001.
34. Kuhn R, Lohler J, Rennick D, Rajewsky K, and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274, 1993.
35. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, and Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277: 33676-33682, 2002.
36. Li MC and He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 10: 620-625, 2004.
37. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP, and Reinecker HC. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 164: 3368-3376, 2000.
38. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, and de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4: 679-691, 2004.
39. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR, and Reinecker HC. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307: 254-258, 2005.
40. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, and Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606, 2001.
41. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, and Scadden DT. Active movement of T cells away from a chemokine. Nat Med 6: 543-548, 2000.
42. Radaeva S, Sun R, Pan HN, Hong F, and Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342, 2004.
43. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD, and Glass DJ. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741, 1999.
44. Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kuhbacher T, Hamling J, Folsch UR, and Seegert D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51: 379-385, 2002.
45. Sotsios Y, Whittaker GC, Westwick J, and Ward SG. The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes. J Immunol 163: 5954-5963, 1999.
46. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, and Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001.
47. Torok HP, Glas J, Tonenchi L, Lohse P, Muller-Myhsok B, Limbersky O, Neugebauer C, Schnitzler F, Seiderer J, Tillack C, Brand S, Bruennler G, Jagiello P, Epplen JT, Griga T, Klein W, Schiemann U, Folwaczny M, Ochsenkuehn T, and Folwaczny C. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 54: 1421-1427, 2005.
48. Veit C, Genze F, Menke A, Hoeffert S, Gress TM, Gierschik P, and Giehl K. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 64: 5291-5300, 2004.
49. Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, and Auernhammer CJ. SOCS-1 and SOCS-3 inhibit IFN-α-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 320: 1007-1014, 2004.
50. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, and Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168: 5342-5351, 2002.
51. Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, Duchrow M, Wohlschlager C, Feller AC, and Stange EF. Human β-defensin 2 but not β-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 14: 745-752, 2002.
52. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, and Stange EF. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 53: 1658-1664, 2004.
53. Whittington HA, Armstrong L, Uppington KM, and Millar AB. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 31: 220-226, 2004.
54. Wolk K, Kunz S, Asadullah K, and Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168: 5397-5402, 2002.
55. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, and Sabat R. IL-22 increases the innate immunity of tissues. Immunity 21: 241-254, 2004.
56. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, and Gurney AL. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 275: 31335-31339, 2000.
57. Yap AS. Initiation of cell locomotility is a morphogenetic checkpoint in thyroid epithelial cells regulated by ERK and PI3-kinase signals. Cell Motil Cytoskeleton 49: 93-103, 2001.